Introduction {#Sec1}
============

Mucinous breast carcinoma (MBC), a special type of breast carcinoma, is the second most common cancer after lobular carcinoma, accounting for 1.3 - 5.4% of all breast cancers (Ellis et al. [@CR8]; Fentiman et al. [@CR9]; Komaki et al. [@CR10]; Scopsi et al. [@CR14]; Anan et al. [@CR1]). According to the current General Rules for Clinical and Pathological Recording of Breast Cancer, MBC is characterized by the fact that the cancer cells produce mucus, and nests of mucinous cancer cells occupy almost the entire tumor mass (Wilson et al. [@CR16]). In the WHO classification of breast tumors, MBC is described as a subtype of mucinous carcinoma and other tumors with abundant mucus (mucin-producing carcinomas) (Ellis et al. [@CR8]). It is histologically subtyped into mixed mucinous breast carcinoma (MMBC) containing a component of conventional invasive ductal carcinoma, and pure mucinous breast carcinoma (PMBC), in which nests of mucinous cancer cells occupy almost the entire tumor mass, and which contains no component of conventional invasive ductal carcinoma (Capella et al. [@CR4]; Ranade et al. [@CR12]; Rosen [@CR13]; André et al. [@CR2]). PMBC may be subtyped into a hypocellular variant (PMBC-A) showing a tubular, cribriform, cord-like, micropapillary or papillary growth pattern, and a hypercellular variant (PMBC-B) growing in solid nests (Capella et al. [@CR4]; Ranade et al. [@CR12]). In this study, we clinicopathologically analyzed MBC according to these subtypes.

Materials and methods {#Sec2}
=====================

Patient background {#Sec3}
------------------

A total of 1,760 patients with primary breast cancer underwent surgery between January 2000 and December 2012. Of these patients, 71 (4.0%) were diagnosed with MBC. These MBC cases were subtyped into MMBC, PMBC-A and PMBC-B for comparison purposes. The median follow-up period was 7.8 years (range, 0.5 -- 10.1 years).

Immunohistochemistry {#Sec4}
--------------------

The hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) expression and proliferative activity, as measured by the Ki67 labeling index, were evaluated by immunohistochemical staining of formalin-fixed, paraffin-embedded surgical breast cancer specimens using the ABC method. For antigen activation, deparaffinized sections were immersed in 0.01 M citrate buffer (pH 6.0), and heated at 105°C for 10 min. Primary antibodies against the ER (clone 1D5, dilution 1:80; Dako, Carpinteria, California, USA), PR (clone PgR636, dilution 1:100; Dako), HER2 (Hercep Test™, Dako) and Ki67 (clone MIB-1, dilution 1:100; Dako) were used. Endogenous peroxidase activity was blocked with 0.3% H~2~O~2~ in methanol, color was developed with DAB (3, 3-diaminobenzidine, tetrahydrochloride) and the sections were counterstained with Meyer's hematoxylin. A pathological diagnosis was made by two pathologists who specialized in mammary gland pathology using the blind method to confirm the objectivity and reproducibility of the diagnosis.

Immunohistochemical scoring {#Sec5}
---------------------------

For the hormone receptors, any staining was considered to indicate a positive sample. HER2 reactivity was assessed according to the ASCO/CAP guidelines. The Ki67 labeling index was evaluated as a percentage of positive cells among more than 1,000 cancer cells in five high-powered fields (HPFs) of the deepest portion and margin of the superficial layer of the tumor, and a percentage of 14% or higher was considered to be positive.

Statistical analysis {#Sec6}
--------------------

Statistical analysis was performed using SPSS version 13.0 statistical software (IBM, Armonk, New York, USA). Clinicopathological factors were analyzed in MBC patients using the chi-square test. Disease-free survival rates were calculated using the Kaplan-Meier method, and significance was assessed using the log-rank test. A value of p \< 0.05 was considered to be significant.

Results {#Sec7}
=======

Of the 1,760 patients who underwent surgery for primary breast cancer, 71 (4.0%), 23 (32.4%), 32 (45.1%) and 16 (22.5%) had MBC, MMB, PMBC-A and PMBC-B, respectively. Table [1](#Tab1){ref-type="table"} shows their clinicopathological characteristics. Their mean age was 61.8 years (range, 26--95 years; median, 64 years). The mean tumor diameter was 3.1 cm (range, 0.5--12.3 cm; median, 2.5 cm). Eight (11.3%), fifteen (21.1%), and 31 patients (43.7%) had lymph node metastasis, vascular invasion and an extensive intraductal component (EIC), respectively. Breast cancer subtyping based on the hormone receptor (HR) and HER2 expression showed that, of the 71 tumors, 68 (95.8%), one (1.4%) and two (2.8%) were HR-positive/HER2-negative, HR-negative/HER2-postive and HR-negative/HER2-negative (so-called triple-negative), respectively. Of the seven patients with recurrence, six (85.7%) had MMBC, none had PMBC-A, one (14.3%) had PMBC-B, and none of the patients had died.Table 1**Demographical data of 71 patients with mucinous carcinoma of the breast**Parameters(n=71)PercentageAgemean 61.8 (26 -- 95, median 64)Tumor diameter (cm)mean 3.1 (0.5 -- 12.3, median 2.5)Tumor location39 (54.9%)/32 (45.1%)     right/leftSubtype23 (32.4%)/32 (45.1%)/16 (22.5%)     MMBC/PMBC-A / PMBC-BPathological stage23 (32.4%)/40 (56.3%)/8 (11.3%)     I/II/IIIpT23 (32.4%)/38 (53.5%)/6 (8.5%)/ 4 (5.6%)     T1/T2/T3/T4pLymph node status8 (11.3%)/63 (88.7%)     Positive/NegativeLymphovascular invasion15 (21.1%)/56 (78.9%)     Positive/NegativeNuclear grade55 (77.5%)/15 (21.1%)/1 (1.4%)     1/2/3EIC31 (43.7%)/40 (56.3%)     Positive/NegativeHormone receptor status68 (95.8%)/3 (4.2%)     Positive/NegativeHER 2 status1 (1.4%)/70 (98.6%)     Positive/NegativeKi678 (11.3%)/63 (88.7%)     Positive/NegativeRecurrence7 (9.9%)/64 (90.1%)     Recurrence/no- RecurrenceRecurrence cases (n=7)6 (85.7%)/0 (0.0%)/1 (14.3%)     MMBC/PMBC-A/PMBC-B*MMBC* mixed mucinous carcinoma, *PMBC* pure mucinous carcinoma, *EIC* extensive intraductal component.

The clinicopathological analysis revealed that MBCs had a significantly larger diameter than non-MBCs (p=0.001), and were significantly more frequently HR-positive (p\<0.001) and negative for HER2 overexpression (p\<0.001) (Table [2](#Tab2){ref-type="table"}).Table 2**Clinicopathologic feature of 71 mucinous breast cancers in 1760 breast carcinomas**ParametersMBC (n=71)Non-MBC(n=1689)p valueAge at operation38 (53.5%)965 (57.1%)0.547  ≤6433 (46.5%)724 (42.9%)  \>64Pathological stage23 (32.4%)799 (47.3%)0.014  I48 (67.6%)890 (52.7%)  II and IIIpTumor size25 (35.2%)937 (55.5%)0.001  ≤2 cm46 (64.8%)752 (45.5%)  \>2 cmpLymph node status63 (88.7%)1270 (75.2%)0.009  Negative8 (11.3%)419 (24.8%)  PositiveLymphovascular invasion56 (78.9%)1276 (75.5%)0.522  Negative15 (21.1%)413 (24.5%)  PositiveHR (ER and/or PR)3 (4.2%)477 (28.2%)\< 0.001  Negative68 (95.8%)1212 (71.8%)  PositiveHER 2 status70 (98.6%)1310 (77.6%)\< 0.001  Negative1 (1.4%)379 (22.4%)  Positive*MBC* mucinous breast carcinoma.*HR* Hormone receptor.

Among all patients (n=1,760), there was no significant difference in the DFS between those with MBC and those with non-MBC tumors (p=0.614, log-rank test) (Figure [1](#Fig1){ref-type="fig"}a). However, a subtype analysis showed that patients with MMBC, PMBC-B or PMBC-A, in this order, had a significantly higher recurrence rate than those with non-MBC tumors (p=0.006, log-rank test) (Figure [1](#Fig1){ref-type="fig"}b). Among the 71 MBCs, MMBC showed a significantly higher Ki67 labeling index (P=0.010) and nuclear grade (p \<0.001) than PMBC, and these were not correlated with the HR or HER2 expression (Table [3](#Tab3){ref-type="table"}). Among the 48 PMBCs, no significant differences in the clinicopathological characteristics were noted between patients with PBMC-A and those with PMBC-B.Figure 1**Correlation between the mucinous carcinoma phenotype and disease**-**free survival in the breast cancer series.** The mixed mucinous breast carcinoma patients experienced significantly poorer outcomes in all breast cancers **(a)** and mucinous carcinomas **(b)**. (NS; not significant).

###### 

**Correlations between subtype and clinicopathological parameters in 71 mucinous breast carcinomas**

  Parameters                MBC (n=71)    p value      PMBC (n=48)   p value                    
  ------------------------- ------------- ------------ ------------- ------------ ------------- -------
  Age at operation          14 (60.9%)    24 (50.0%)   0.390         14 (43.8%)   10 (62.5%)    0.220
    ≤64                     9 (39.1%)     24 (50.0%)                 18 (56.2%)   6 (37.5%)     
    \>64                                                                                        
  Pathological stage        9 (39.1%)     14 (29.2%)   0.401         8 (25.0%)    6 (37.5%)     0.369
    I                       14 (60.9%)    34 (70.8%)                 24 (75.0%)   10 (62.5%)    
    II and III                                                                                  
  pTumor size               11 (47.8%)    14 (29.2%)   0.123         8 (25.0%)    6 (37.5%)     0.175
    ≤2 cm                   12 (52.2%)    34 (70.8%)                 24 (75.0%)   10 (62.5%)    
    \>2 cm                                                                                      
  pLymph node status        19 (82.6%)    44 (91.7%)   0.162         30 (93.8%)   14 (87.5%)    0.460
    Negative                4 (17.4%)     4 (8.3%)                   2 (6.2%)     2 (12.5%)     
    Positive                                                                                    
  Lymphovascular invasion   16 (69.6%)    40 (83.3%)   0.184         29 (90.6%)   11 (68.8%)    0.057
    Negative                7 (30.4%)     8 (16.7%)                  3 (9.4%)     5 (32.2%)     
    Positive                                                                                    
  HR (ER and / or PR)       1 (4.3%)      2 (4.2%)     0.454         1 (3.1%)     1 (6.3%)      0.453
    Negative                22 (95.7%)    46 (95.8%)                 31 (96.9%)   15 (93.7%)    
    Positive                                                                                    
  HER2 status               23 (100.0%)   47 (97.9%)   0.676         31 (96.9%)   16 (100.0%)   0.667
    Negative                0 (0.0%)      1 (2.1%)                   1 (3.1%)     0 (0.0%)      
    Positive                                                                                    
  Ki67                      17 (73.9%)    46 (95.8%)   0.010         30 (93.8%)   16 (100.0%)   0.439
    Negative                6 (26.1%)     2 (4.2%)                   2 (6.2%)     0 (0.0%)      
    Positive                                                                                    
  Nuclear grade             11 (47.8%)    44 (91.7%)   \< 0.001      30 (93.8%)   14 (87.5%)    0.306
    1                       12 (52.2%)    4 (8.3%)                   2 (6.2%)     2 (22.5%)     
    2 and 3                                                                                     
  EIC                       12 (52.2%)    28 (58.3%)   0.624         20 (62.5%)   8 (50.0%)     0.174
    Negative                11 (47.8%)    20 (41.7%)                 12 (37.5%)   8 (50.0%)     
    Positive                                                                                    

*BMC* breast mucinous carcinoma, *MMBC* mixed mucinous carcinoma, *PMBC* pure mucinous carcinoma, *HR* Hormone receptor, *EIC* extensive intraductal component.

The patients with recurrence were divided into those with and without lymph node metastasis, and their primary tumors and metastatic lymph nodes were pathologically examined. As a result, other pathological types coexisting with MBC (Figure [2](#Fig2){ref-type="fig"}a) were also confirmed to be present in the metastatic lymph nodes (Figure [2](#Fig2){ref-type="fig"}b). A mucus-rich lesion, as seen in the primary tumor (Figure [2](#Fig2){ref-type="fig"}c), was also observed in the metastatic lymph nodes (Figure [2](#Fig2){ref-type="fig"}d) of the patients with PMBC-A who had no recurrence in the presence of lymph node metastasis.Figure 2**Histological findings** (**H**.**E**. **stain x 400). (a)** primary lesion of mixed mucinous breast carcinoma. **(b)** metastatic lymph node of mixed mucinous breast carcinoma. **(c)** primary lesion of pure mucinous breast carcinoma type A. **(d)** metastatic lymph node of pure mucinous breast carcinoma type A.

Discussion {#Sec8}
==========

It has been reported that MBC shows a favorable prognosis, with a 10-year survival rate of more than 90% (Fentiman et al. [@CR9]; Komaki et al. [@CR10]; Di Saverio et al. [@CR6]). Since a higher ratio of the extracellular mucus component to the cancer cell component is associated with a more favorable prognosis, PMBC-A, PMBC-B and MMBC, in this order, would be expected to show a favorable prognosis (Komaki et al. [@CR10]; Ranade et al. [@CR12]; Clayton [@CR5]). In this study, there was no significant difference in the DFS between the patients with MBC and those with non-MBC tumors. However, a subtype analysis showed that patients with MMBC had a significantly higher recurrence rate than those with PMBC, suggesting the usefulness of breast cancer sub-classification.

Of the seven patients with recurrence in the present study, six (85.7%) had MMBC, none had PMBC-A and one (14.3%) had PMBC-B. Of the eight patients with lymph node metastasis, four (three with MMBC and one with PMBC-B) had recurrence. On the other hand, two patients with PMBC-A had no recurrence in the presence of lymph node metastasis. This suggests that PMBC-A with a high proportion of mucus shows a favorable prognosis even in the presence of lymph node metastasis.

From the viewpoint of the intrinsic subtype, MBC tumors were frequently HR-positive/HER2-negative, and often of the so-called luminal A type (Ki67 labeling index \<14%). Many researchers have reported that most MBCs are luminal A type, and that this is a clinicopathological characteristic of MBC (Komaki et al. [@CR10]; Diab et al. [@CR7]; Cao et al. [@CR3]; Shousha et al. [@CR15]). Hormone therapy is a common treatment option used for patients with luminal A-type breast cancer, but some MBCs are resistant to treatment, suggesting that MMBC, which are considered to have a relatively poor prognosis based on the present results, may have different biological properties even within the same tumor type.

Thus, with regard to the therapeutic strategies based on the sub-classification of mucinous carcinoma of the mammary gland, "standard treatment" for a coexisting histological type should be performed in patients with MMBC, which shows a high recurrence rate (NCCN Clinical Practice Guidelines in Oncology Breast Cancer v.2 [@CR11]). Among patients with PMBC, "standard treatment" or "treatment for a histological type with a favorable prognosis" should be selected based on the presence or absence of lymph node metastasis in those with PMBC-B. On the other hand, in those with PMBC-A, "treatment for a histological type with a favorable prognosis" may be selected, regardless of the presence or absence of lymph node metastasis.

In the NCCN guidelines, MBC is also regarded as "a histological type with a favorable prognosis" in a uniform manner, and "treatment for a histological type with a favorable prognosis" is recommended. However, the results of this study suggest that sub-classification-based, individualized therapeutic strategies should therefore be considered.
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